Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study
Eurasian Journal of Medicine and Oncology · 03.07.2026 · 026200224
DOI: 10.36922/ejmo026200224 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 03.07.2026. Verfasst von Wenna Hu und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Breast cancer susceptibility gene 1/2 (BRCA1/2) mutations are implicated in ovarian cancer biology and may influence tumor phenotype, treatment response, and prognosis.
Objective
To compare clinicopathological characteristics and survival outcomes between BRCA-mutated and BRCA wild-type ovarian cancer patients in a multicenter cohort.
Methods
This retrospective cohort study included ovarian cancer patients who underwent BRCA1/2 testing at three hospitals in China from January 2018 to December 2024. Clinicopathological variables were compared between groups. Disease-free survival (DFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models.
Results
Among 316 patients, 117 (37.0%) had BRCA mutations and 199 (63.0%) were BRCA wild-type. BRCA-mutated patients had a higher proportion with serous histology (94.9% vs. 87.4%, p = 0.032) and a more frequent use of poly(ADP-ribose) polymerase (PARP) inhibitors (47.9% vs. 20.1%, p < 0.001). They also had lower crude recurrence (49.6% vs. 73.4%, p < 0.001) and mortality rates (28.2% vs. 44.2%, p = 0.006). After adjustment, BRCA mutation status was not independently associated with DFS or OS. Advanced International Federation of Gynecology and Obstetrics (FIGO) stage, neoadjuvant chemotherapy, bilateral tumors, and residual disease > 1 cm were independently associated with shorter DFS, whereas use of a vascular endothelial growth factor inhibitor was associated with longer DFS. Advanced FIGO stage was associated with worse OS, while PARP inhibitor maintenance therapy was associated with longer OS.
Conclusion
BRCA-mutated patients showed better crude outcomes, but the survival difference was attenuated after multivariable Cox adjustment. BRCA testing remains valuable for guiding individualized maintenance therapy.
Zitieren
APA
Hu, W., Sun, Z., Zhang, D., Li, N., Song, X., Tian, W., Liu, M., Chu, R., & Zhang, S. (2026). Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study. Eurasian Journal of Medicine and Oncology, 0(0), 026200224. https://doi.org/10.36922/ejmo026200224
Vancouver
Hu W, Sun Z, Zhang D, Li N, Song X, Tian W, et al. Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study. Eurasian Journal of Medicine and Oncology. 2026;0(0):026200224. doi:10.36922/ejmo026200224
BibTeX
@article{Hu2026,
author = {Hu, Wenna and Sun, Zhen and Zhang, Dehui and Li, Na and Song, Xiao and Tian, Wei and Liu, Ming and Chu, Ran and Zhang, Shuo},
title = {Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {0},
number = {0},
pages = {026200224},
doi = {10.36922/ejmo026200224}
}
EUVIMED